

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	APR 02	CAS Registry Number Crossover Limits Increased to 500,000 in Key STN Databases
NEWS	3	APR 02	PATDPAFULL: Application and priority number formats enhanced
NEWS	4	APR 02	DWPI: New display format ALLSTR available
NEWS	5	APR 02	New Thesaurus Added to Derwent Databases for Smooth Sailing through U.S. Patent Codes
NEWS	6	APR 02	EMBASE Adds Unique Records from MEDLINE, Expanding Coverage back to 1948
NEWS	7	APR 07	50,000 World Traditional Medicine (WTM) Patents Now Available in CAPlus
NEWS	8	APR 07	MEDLINE Coverage Is Extended Back to 1947
NEWS	9	JUN 16	WPI First View (File WPIFV) will no longer be available after July 30, 2010
NEWS	10	JUN 18	DWPI: New coverage - French Granted Patents
NEWS	11	JUN 18	CAS and FIZ Karlsruhe announce plans for a new STN platform
NEWS	12	JUN 18	IPC codes have been added to the INSPEC backfile (1969-2009)
NEWS	13	JUN 21	Removal of Pre-IPC 8 data fields streamline displays in CA/CAPlus, CASREACT, and MARPAT
NEWS	14	JUN 21	Access an additional 1.8 million records exclusively enhanced with 1.9 million CAS Registry Numbers -- EMBASE Classic on STN
NEWS	15	JUN 28	Introducing "CAS Chemistry Research Report": 40 Years of Biofuel Research Reveal China Now Atop U.S. in Patenting and Commercialization of Bioethanol
NEWS	16	JUN 29	Enhanced Batch Search Options in DGENE, USGENE, and PCTGEN
NEWS	17	JUL 19	Enhancement of citation information in INPADOC databases provides new, more efficient competitor analyses
NEWS	18	JUL 26	CAS coverage of global patent authorities has expanded to 61 with the addition of Costa Rica
NEWS	19	SEP 15	MEDLINE Cited References provide additional relevant records with no additional searching.
NEWS	20	OCT 04	Removal of Pre-IPC 8 data fields streamlines displays in USPATFULL, USPAT2, and USPATOLD.
NEWS	21	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS	22	OCT 06	Increase your retrieval consistency with new formats for Taiwanese application numbers in CA/CAPlus.
NEWS	23	OCT 21	CA/CAPlus kind code changes for Chinese patents increase consistency, save time

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:00:37 ON 21 OCT 2010

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 12:00:46 ON 21 OCT 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 OCT 2010 HIGHEST RN 1246733-76-5
DICTIONARY FILE UPDATES: 20 OCT 2010 HIGHEST RN 1246733-76-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\722ab.str



```

chain nodes :
1  2  3  4  5 12 21 22 23 24 27 28 29 31 32 36 37
ring nodes :
13 16 17 18 19 20
chain bonds :
1-2 1-3 1-12 2-4 3-5 12-13 21-22 22-23 22-31 23-24 24-27 24-28 28-29
31-32 32-36 32-37
ring bonds :
13-16 13-20 16-17 17-18 18-19 19-20
exact/norm bonds :
2-4 3-5 24-27 24-28 28-29 32-36 32-37
exact bonds :
1-2 1-3 1-12 12-13 21-22 22-23 22-31 23-24 31-32
normalized bonds :
13-16 13-20 16-17 17-18 18-19 19-20

```

G1:H,Hy,Cb,Cy,Ak

G2:H,Ak

G3:H,Cy,Ak

Match level :

```

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 12:CLASS 13:Atom 16:Atom 17:Atom
18:Atom 19:Atom 20:Atom 21:CLASS 22:CLASS 23:CLASS 24:CLASS 27:CLASS
28:CLASS 29:CLASS 31:CLASS 32:CLASS 36:CLASS 37:CLASS 38:Atom

```

L1 STRUCTURE UPLOADED

```

=> s l1 sss full
FULL SEARCH INITIATED 12:01:06 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 174279 TO ITERATE

```

100.0% PROCESSED 174279 ITERATIONS 73 ANSWERS
SEARCH TIME: 00.00.01

L2 73 SEA SSS FUL L1

```

=> file capl
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 191.54 191.76

```

FILE 'CAPLUS' ENTERED AT 12:01:10 ON 21 OCT 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Oct 2010 VOL 153 ISS 17
FILE LAST UPDATED: 20 Oct 2010 (20101020/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 8 L2

=> d l3 1-8 ibib hitstr

L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:227243 CAPLUS
DOCUMENT NUMBER: 146:295922
TITLE: Process for preparation of benzonitrile derivatives as bactericides
INVENTOR(S): Iwama, Hideki; Sudo, Junko; Shimizu, Susumu; Katohno, Masataka; Yamamoto, Masashi; Suzuki, Shigeru; Hoshino, Hiroshi; Kuruwara, Nanako
PATENT ASSIGNEE(S): Kureha Corporation, Japan
SOURCE: PCT Int. Appl., 120pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007023788	A1	20070301	WO 2006-JP316371	20060822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

US 20080293951 A1 20081127 US 2008-990786 20080221
PRIORITY APPLN. INFO.: JP 2005-239518 A 20050822
WO 2006-JP316371 W 20060822

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): CASREACT 146:295922; MARPAT 146:295922

IT 864911-78-4P, [[4-(Dipropylamino)butyl][4-[[[(1H-imidazol-2-yl)methyl][(1-methylimidazol-2-yl)methyl]amino]methyl]benzyl]amino]acetic acid ethyl ester

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of benzonitrile derivs. as bactericides)

RN 864911-78-4 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-yl)methyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, ethyl ester
(CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:945529 CAPLUS

DOCUMENT NUMBER: 145:342420

TITLE: Pharmaceutical compositions comprising amine compounds

INVENTOR(S): Niimura, Koichi; Kikumoto, Shigeyuki; Yamamoto,
Masashi; Tohmiya, Hiraku

PATENT ASSIGNEE(S): Kureha Corporation, Japan

SOURCE: PCT Int. Appl., 75pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006095542	A1	20060914	WO 2006-JP302629	20060215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,				
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,				

SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: JP 2005-60437 A 20050304

OTHER SOURCE(S): MARPAT 145:342420

IT 864911-71-7P 864911-79-5P 909570-54-3P


909570-55-4P 909570-60-1P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(stabilization of pharmacol. active amine compds. in drug delivery systems)

RN 864911-71-7 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 864911-79-5 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, ethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 864911-78-4

CMF C31 H49 N7 O2




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 909570-54-3 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl]methyl]amino]methyl]phenylmethyl]-, ethyl ester, compd. with β -cyclodextrin (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 864911-78-4

CMF C31 H49 N7 O2




CM 2

CRN 7585-39-9

CMF C42 H70 O35

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 909570-55-4 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, ethyl ester, compd. with γ -cyclodextrin (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 864911-78-4


CMF C31 H49 N7 O2



CM 2

CRN 17465-86-0

CMF C48 H80 O40




RN 909570-60-1 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, compd. with γ -cyclodextrin (1:4) (9CI) (CA INDEX NAME)

CM 1

CRN 864912-46-9


CMF C29 H45 N7 O2



CM 2

CRN 17465-86-0

CMF C48 H80 O40




IT	864911-59-1	864911-78-4	864912-33-4
	864912-46-9	864912-50-5	864912-54-9
	864912-55-0	864912-66-3	864912-67-4
	865061-29-6		

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(stabilization of pharmacol. active amine compds. in drug delivery systems)


RN 864911-59-1 CAPLUS

CN β-Alanine, N-[[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, ethyl ester (CA INDEX NAME)




RN 864911-78-4 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl](1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, ethyl ester
(CA INDEX NAME)




RN 864912-33-4 CAPLUS

CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl](1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, methyl ester
(CA INDEX NAME)




RN 864912-46-9 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-([4-[(1H-imidazol-2-ylmethyl)](1-methyl-1H-imidazol-2-yl)methyl]amino)methyl]phenyl)methyl]- (CA INDEX NAME)



RN 864912-50-5 CAPLUS


CN β -Alanine, N-[4-[[bis(1H-imidazol-2-ylmethyl)amino)methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]- (CA INDEX NAME)



RN 864912-54-9 CAPLUS


CN β -Alanine, N-[4-[[bis(1H-imidazol-2-

ylmethyl)amino]methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]-, methyl ester (CA INDEX NAME)




RN 864912-55-0 CAPLUS

CN Glycine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]-, methyl ester (CA INDEX NAME)




RN 864912-66-3 CAPLUS


CN Glycine, N-[[4-[[bis[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]- (CA INDEX NAME)



RN 864912-67-4 CAPLUS
 CN Glycine, N-[[4-[[bis[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, ethyl ester (CA INDEX NAME)



RN 865061-29-6 CAPLUS
 CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl] [(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2005:1004718 CAPLUS
 DOCUMENT NUMBER: 143:306311
 TITLE: Preparation of N-arylmethyl or
 N-heterocyclylmethyl-N-(imidazol-2-ylmethyl)amines as
 antagonists of chemokine receptor CXCR4
 INVENTOR(S): Saitou, Atsushi; Kikumoto, Shigeyuki; Ono, Masahiro;
 Matsui, Ryo; Yamamoto, Masashi; Sawa, Tomohiro;
 Suzuki, Shigeru; Yanaka, Mikiro
 PATENT ASSIGNEE(S): Kureha Chemical Industry Company, Limited, Japan
 SOURCE: PCT Int. Appl., 252 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085209	A1	20050915	WO 2005-JP4189	20050310
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2558600	A1	20050915	CA 2005-2558600	20050310
EP 1724263	A1	20061122	EP 2005-720460	20050310
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1950343	A	20070418	CN 2005-80014925	20050310
JP 3977411	B2	20070919	JP 2006-510807	20050310
KR 2006131969	A	20061220	KR 2006-7020943	20061009
US 20070208007	A1	20070906	US 2006-591722	20061030
JP 2007091755	A	20070412	JP 2007-1425	20070109
JP 4028885	B2	20071226		
JP 2007126476	A	20070524	JP 2007-1426	20070109
PRIORITY APPLN. INFO.:			JP 2004-68229	A 20040310
			JP 2004-350599	A 20041203
			JP 2006-510807	A3 20050310
			WO 2005-JP4189	W 20050310

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 143:306311

IT 864911-20-6P	864911-36-4P	864911-40-0P
864911-42-2P	864911-43-3P	864911-44-4P
864911-45-5P	864911-46-6P	864911-47-7P
864911-48-8P	864911-49-9P	864911-50-2P
864911-51-3P	864911-53-5P	864911-54-6P
864911-55-7P	864911-56-8P	864911-58-0P
864911-59-1P	864911-60-4P	864911-61-5P
864911-62-6P	864911-64-8P	864911-70-6P
864911-71-7P	864911-72-8P	864911-73-9P
864911-74-0P	864911-75-1P	864911-76-2P
864911-77-3P	864911-78-4P	864911-79-5P
864911-80-8P	864911-81-9P	864911-82-0P
864911-85-3P	864911-88-6P	864911-89-7P


864911-90-0P	864911-92-2P	864912-33-4P
864912-46-9P	864912-48-1P	864912-50-5P
864912-53-8P	864912-54-9P	864912-55-0P
864912-56-1P	864912-57-2P	864912-58-3P
864912-59-4P	864912-60-7P	864912-61-8P
864912-63-0P	864912-66-3P	864912-67-4P
864912-68-5P	864912-70-9P	864914-23-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-arylmethyl or N-heterocyclylmethyl-N-(imidazol-2-ylmethyl)amines as antagonists of chemokine receptor CXCR4 for treating HIV viral infectious diseases, rheumatism, or cancer metastasis)

RN 864911-20-6 CAPLUS


CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 864911-36-4 CAPLUS

CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 864911-40-0 CAPLUS
 CN 1H-Imidazole-1-acetic acid, 2-[[[4-[[[(carboxymethyl)[4-(dipropylamino)butylamino]methyl]phenyl]methyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl

RN 864911-42-2 CAPLUS
 CN β-Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-yl)methyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 864911-43-3 CAPLUS

CN β-Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl-, 1-methylethyl ester (CA INDEX NAME)




RN 864911-44-4 CAPLUS

CN β-Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl-, phenylmethyl ester (CA INDEX NAME)





RN 864911-45-5 CAPLUS

CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl] (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, butyl ester (CA INDEX NAME)




RN 864911-46-6 CAPLUS


CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl] (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (CA INDEX NAME)




RN 864911-47-7 CAPLUS
 CN 2,4-Dioxo-8,13-diazahexadecanoic acid,
 8-[[4-[[1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-5-oxo-13-propyl-, 1-ethylpropyl
 ester (CA INDEX NAME)




RN	864911-48-8	CAPLUS
CN	2,4-Dioxo-8,13-diazahexadecanoic acid, 8-[[4-[(1H-imidazol-2-yl)methyl] (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl[methyl]-3-methyl-5-oxo-13-propyl-, 1-ethylpropyl ester (CA INDEX NAME)	




RN 864911-49-9 CAPLUS
CN 2,4-Dioxo-8,13-diazahexadecanoic acid,
8-[[4-[[[(1H-imidazol-2-yl)methyl][(1-methyl-1H-imidazol-2-yl)methyl]amino)methyl]phenyl]methyl]-5-oxo-13-propyl-, methyl ester (CA
INDEX NAME)



RN 864911-50-2 CAPLUS
 CN 2,4-Dioxo-8,13-diazahexadecanoic acid,
 8-[[4-[[[(1H-imidazol-2-ylmethyl) [(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-5-oxo-13-propyl-, ethyl ester (CA INDEX NAME)




RN 864911-51-3 CAPLUS
 CN 2,4-Dioxo-8,13-diazahexadecanoic acid,
 8-[[4-[[[(1H-imidazol-2-ylmethyl) [(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-5-oxo-13-propyl-, 1,1-dimethylethyl ester (CA INDEX NAME)





RN 864911-53-5 CAPLUS

CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, [(1-oxohexyl)oxy]methyl ester (CA INDEX NAME)




RN 864911-54-6 CAPLUS

CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, (3-cyclopentyl-1-oxopropoxy)methyl ester (CA INDEX NAME)




RN 864911-55-7 CAPLUS
 CN β-Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, [[(diethylamino)carbonyl]oxy]methyl ester (CA INDEX NAME)




RN 864911-56-8 CAPLUS

CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl] (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, 2-(1,1-dimethylethoxy)-2-oxoethyl ester (CA INDEX NAME)




RN 864911-58-0 CAPLUS

CN β -Alanine, N-[[4-[[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, hydrochloride (9CI) (CA INDEX NAME)





● x HCl



RN 864911-59-1 CAPLUS
 CN β-Alanine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino)methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]-, ethyl ester (CA INDEX NAME)




RN 864911-60-4 CAPLUS
 CN β-Alanine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino)methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester (CA INDEX NAME)



RN 864911-61-5 CAPLUS
 CN 2,4-Dioxa-8,13-diazahexadecanoic acid,
 8-[[4-[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-3-methyl-5-
 oxo-13-propyl-, cyclohexyl ester (CA INDEX NAME)




RN 864911-62-6 CAPLUS
 CN β-Alanine, N-[[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, (2,2-dimethyl-1-oxopropoxy)methyl ester (CA INDEX NAME)




RN 864911-64-8 CAPLUS

CN β-Alanine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, [[(diethylamino)carbonyl]oxy]methyl ester (CA INDEX NAME)




RN 864911-70-6 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl](1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 864911-71-7 CAPLUS
 CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 864911-72-8 CAPLUS
 CN 2,4-Dioxo-8,13-diazahexadecanoic acid, 8-[[4-[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-3-methyl-5-oxo-13-propyl-, 1-methylethyl ester (CA INDEX NAME)




RN 864911-73-9 CAPLUS
 CN β-Alanine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 864911-74-0 CAPLUS
 CN Glycine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, methyl ester, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 864911-75-1 CAPLUS


CN Glycine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[[4-(dipropylamino)butyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 864911-76-2 CAPLUS


CN Glycine, N-[[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, phenylmethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 864911-77-3 CAPLUS
 CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl] [(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]-, 2-(4-morpholinyl)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A






● x HCl

RN 864911-78-4 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl)](1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 864911-79-5 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl)](1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, ethyl ester, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 864911-78-4

CMF C31 H49 N7 O2




CM 2

CRN 87-69-4


CMF C4 H6 O6

Absolute stereochemistry.



RN 864911-80-8 CAPLUS


CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl] (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, 2-methoxyethyl ester, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 864911-81-9 CAPLUS


CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl) (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]-, 3-phenyl-2-propenyl ester, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 864911-82-0 CAPLUS


CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl) (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]-, 2-(2-hydroxyethoxy)ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 864911-85-3 CAPLUS

CN Glycine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 864911-88-6 CAPLUS
 CN Glycine, N-[[4-[[bis[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 864911-89-7 CAPLUS
 CN Glycine, N-[[4-[[bis[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 864911-90-0 CAPLUS
 CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, [(2R)-tetrahydro-2-furanyl]methyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 864911-92-2 CAPLUS
 CN Glycine, N-[4-[(carboxymethyl)[4-[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]amino]butyl]-N-propyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 864912-33-4 CAPLUS

CN β -Alanine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]-, methyl ester (CA INDEX NAME)




RN 864912-46-9 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]- (CA INDEX NAME)




RN 864912-48-1 CAPLUS

CN 1H-Imidazole-1-acetic acid, 2-[[[[4-[(carboxymethyl)[4-(dipropylamino)butyl]amino]methyl]phenyl]methyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]- (CA INDEX NAME)




RN 864912-50-5 CAPLUS

CN β -Alanine, N-[4-[4-[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]- (CA INDEX NAME)




RN 864912-53-8 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[4-[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, methyl ester (CA INDEX NAME)




RN 864912-54-9 CAPLUS

CN β -Alanine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, methyl ester (CA INDEX NAME)




RN 864912-55-0 CAPLUS

CN Glycine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, methyl ester (CA INDEX NAME)




RN 864912-56-1 CAPLUS

CN Glycine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[[4-(dipropylamino)butyl]- (CA INDEX NAME)



RN 864912-57-2 CAPLUS


CN Glycine, N-[[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, phenylmethyl ester (CA INDEX NAME)




RN 864912-58-3 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl] (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]-,
2-(4-morpholinyl)ethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 864912-59-4 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[1H-imidazol-2-ylmethyl] (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]-,
2-methoxyethyl ester (CA INDEX NAME)




RN 864912-60-7 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl) (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, 3-phenyl-2-propen-1-yl ester (CA INDEX NAME)




RN 864912-61-8 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl) (1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, 2-(2-hydroxyethoxy)ethyl ester (CA INDEX NAME)




RN 864912-63-0 CAPLUS

CN Glycine, N-[[4-[[bis(1H-imidazol-2-ylmethyl)amino]methyl]phenyl]methyl]-N-[4-(diisopropylamino)butyl]-, ethyl ester (CA INDEX NAME)




RN 864912-66-3 CAPLUS

CN Glycine, N-[[4-[[bis[(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-N-[4-(diisopropylamino)butyl]- (CA INDEX NAME)



RN 864912-67-4 CAPLUS


CN Glycine, N-[[4-[[bis[(1-methyl-1H-imidazol-2-yl)methyl]amino)methyl]phenyl)methyl]-N-[4-(dipropylamino)butyl]-, ethyl ester (CA INDEX NAME)



RN 864912-68-5 CAPLUS


CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino)methyl]phenyl)methyl]-, [(2S)-tetrahydro-2-furanyl)methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 864912-70-9 CAPLUS

CN Glycine, N-[4-[(carboxymethyl)[4-[[[(1H-imidazol-2-ylmethyl)[(1-methyl-1H-imidazol-2-yl)methyl]amino)methyl]phenyl)methyl]amino]butyl]-N-propyl- (9CI) (CA INDEX NAME)



RN 864914-23-8 CAPLUS

CN Glycine, N-[4-(dipropylamino)butyl]-N-[[4-[(1H-imidazol-2-ylmethyl) [(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na


IT 864914-10-3P 864914-29-4P 864914-38-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-arylmethyl or N-heterocyclymethyl-N-(imidazol-2-ylmethyl)amines as antagonists of chemokine receptor CXCR4 for treating HIV viral infectious diseases, rheumatism, or cancer metastasis)


RN 864914-10-3 CAPLUS

CN 1H-imidazole-1-acetic acid, 2-[[[4-[[[4-(dipropylamino)butyl] (2-methoxy-2-oxoethyl)amino]methyl]phenyl]methyl] [(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]-, methyl ester (CA INDEX NAME)




RN 864914-29-4 CAPLUS

CN Glycine, N-[4-[[bis[(1-methyl-1H-benzimidazol-2-yl)methyl]amino]methyl]phenyl]methyl]-N-[4-(dipropylamino)butyl]-, methyl ester (CA INDEX NAME)



RN 864914-38-5 CAPLUS

CN Glycine, N-[4-[(2-ethoxy-2-oxoethyl)[[4-[[1H-imidazol-2-ylmethyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]methyl]phenyl)methyl]amino]butyl]-N-propyl-, ethyl ester (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:578453 CAPLUS

DOCUMENT NUMBER: 122:314275

ORIGINAL REFERENCE NO.: 122:57153a, 57156a

TITLE: Preparation of complexes possessing ortho ligating functionality

INVENTOR(S): Wilson, David A.; Garlich, Joseph R.; Frank, R. Keith; Mcmillan, Kenneth; Simon, Jaime

PATENT ASSIGNEE(S): Dow Chemical Co., USA

SOURCE: U.S., 22 pp. Cont.-in-part of U.S. Ser. No. 421,452, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5342604	A	19940830	US 1992-900808	19920617
HU 69174	A2	19950828	HU 1991-1928	19910610
HU 215932	B	19990329		
HU 69173	A2	19950828	HU 1991-1929	19910610
US 5696239	A	19971209	US 1995-468957	19950606
FI 9505078	A	19951025	FI 1995-5078	19951025
FI 9505079	A	19951025	FI 1995-5079	19951025
US 5714631	A	19980203	US 1996-597335	19960206
KR 153500	B1	19981201	KR 1998-10886	19980328
KR 153501	B1	19981201	KR 1998-10887	19980328
PRIORITY APPLN. INFO.:			US 1988-265158	B2 19881031
			US 1989-421452	B2 19891013
			FI 1989-5141	A 19891030
			HU 1989-5608	A 19891030
			KR 1989-15647	A 19891030
			US 1992-900809	B3 19920617

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 122:314275

IT 132219-77-3DP, yttrium complexes 132219-77-3P
 132219-78-4DP, samarium complexes 132219-78-4P
 132219-79-5P 132219-80-8DP, yttrium complexes
 132219-80-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylaminocarboxylate, as antitumor agent and for treatment of bone pain)


RN 132219-77-3 CAPLUS

CN Glycine, N,N'-[5-(acetylamino)-2-hydroxy-1,3-phenylene]bis(methylene)bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI)
 (CA INDEX NAME)




RN 132219-77-3 CAPLUS


CN Glycine, N,N'-[5-(acetylamino)-2-hydroxy-1,3-phenylene]bis(methylene)bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI)
 (CA INDEX NAME)




RN 132219-78-4 CAPLUS
 CN Glycine, N,N'-[(5-amino-2-hydroxy-1,3-phenylene)bis(methylene)]bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 132219-78-4 CAPLUS
 CN Glycine, N,N'-[(2-amino-5-hydroxy-1,3-phenylene)bis(methylene)]bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 132219-79-5 CAPLUS
 CN Glycine, N,N'-[(2-hydroxy-5-isothiocyanato-1,3-phenylene)bis(methylene)]bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 132219-80-8 CAPLUS
 CN Glycine, N-[[5-(acetylamino)-3-[[bis(carboxymethyl)amino]methyl]-2-hydroxyphenyl]methyl]-N-[2-[[bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 132219-80-8 CAPLUS
 CN Glycine, N-[[5-(acetylamino)-3-[[bis(carboxymethyl)amino]methyl]-2-hydroxyphenyl]methyl]-N-[2-[[bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 1991:525667 CAPLUS
 DOCUMENT NUMBER: 115:125667
 ORIGINAL REFERENCE NO.: 115:21311a, 21314a
 TITLE: Process for preparing isothiocyanato functionalized metal complexes
 INVENTOR(S): Fazio, Michael J.; Pollock, Douglas K.; Kotite, Nicolas J.

PATENT ASSIGNEE(S): Dow Chemical Co., USA
 SOURCE: Eur. Pat. Appl., 17 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 374947	A1	19900627	EP 1989-123768	19891222
EP 374947	B1	19950308		
R: BE, CH, DE, ES, FR, GB, GR, IT, LI, NL				
US 5006643	A	19910409	US 1989-383103	19890720
WO 9007342	A1	19900712	WO 1989-US5785	19891215
W: BR, JP				
BR 8907282	A	19910312	BR 1989-7282	19891215
JP 03502937	T	19910704	JP 1990-501909	19891215
JP 2930708	B2	19990803		
CA 2006372	C	20020702	CA 1989-2006372	19891221
DK 8906655	A	19900624	DK 1989-6655	19891222
NO 8905236	A	19900625	NO 1989-5236	19891222
CN 1044461	A	19900808	CN 1989-109820	19891222
CN 1025735	C	19940824		
HU 52778	A2	19900828	HU 1989-6768	19891222
HU 209459	B	19940628		
ES 2068881	T3	19950501	ES 1989-123768	19891222
IL 92860	A	19950831	IL 1989-92860	19891222
KR 163758	B1	19990115	KR 1989-19262	19891222
FI 105332	B1	20000731	FI 1989-6248	19891222
PRIORITY APPLN. INFO.:			US 1988-289172	A 19881223
			US 1989-383103	A 19890720
			US 1987-65739	A2 19870624
			US 1988-211496	B2 19880624
			US 1988-265158	B2 19881031
			US 1989-370956	A2 19890621
			WO 1989-US5785	A 19891215

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

IT 132219-78-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, in preparation of isothiocyanate compds. for metal complexes)
 RN 132219-78-4 CAPLUS
 CN Glycine, N,N'-[(5-amino-2-hydroxy-1,3-phenylene)bis(methylene)]bis[N-[2-bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

ACCESSION NUMBER: 1991:117859 CAPLUS
 DOCUMENT NUMBER: 114:117859
 ORIGINAL REFERENCE NO.: 114:19977a,19980a
 TITLE: Chelants possessing ortho ligating functionality and complexes thereof
 INVENTOR(S): Wilson, David A.; Garlich, Joseph R.; Frank, Richard K.; McMillan, Kenneth; Simon, Jaime
 PATENT ASSIGNEE(S): Dow Chemical Co., USA
 SOURCE: Eur. Pat. Appl., 39 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 8
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 367223	A2	19900509	EP 1989-120190	19891031
EP 367223	A3	19900905		
EP 367223	B1	19950426		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
CA 2001765	A1	19900430	CA 1989-2001765	19891030
CA 2001765	C	20031230		
DK 8905413	A	19900501	DK 1989-5413	19891030
NO 8904326	A	19900502	NO 1989-4326	19891030
NO 178571	B	19960115		
NO 178571	C	19960424		
HU 51594	A2	19900528	HU 1989-5608	19891030
HU 207710	B	19930528		
CN 1042536	A	19900530	CN 1989-108398	19891030
CN 1038929	C	19980701		
JP 02196761	A	19900803	JP 1989-282843	19891030
JP 2845328	B2	19990113		
AU 8943916	A	19901004	AU 1989-43916	19891030
AU 628095	B2	19920910		
IL 92160	A	19940731	IL 1989-92160	19891030
KR 153468	B1	19981201	KR 1989-15647	19891030
BR 8905657	A	19900605	BR 1989-5657	19891031
ZA 8908271	A	19910626	ZA 1989-8271	19891031
EP 566166	A1	19931020	EP 1993-110123	19891031
EP 566166	B1	19960925		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
EP 570022	A2	19931118	EP 1993-110124	19891031
EP 570022	A3	19931124		
EP 570022	B1	19960731		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
AT 121727	T	19950515	AT 1989-120190	19891031
AT 140917	T	19960815	AT 1993-110124	19891031
AT 143353	T	19961015	AT 1993-110123	19891031
ES 2090787	T3	19961016	ES 1993-110124	19891031
ES 2092188	T3	19961116	ES 1993-110123	19891031
HU 69174	A2	19950828	HU 1991-1928	19910610
HU 215932	B	19990329		
HU 69173	A2	19950828	HU 1991-1929	19910610
CN 1090286	A	19940803	CN 1993-118881	19931021
CN 1045290	C	19990929		
US 5696239	A	19971209	US 1995-468957	19950606
FI 9505078	A	19951025	FI 1995-5078	19951025
FI 9505079	A	19951025	FI 1995-5079	19951025
US 5714631	A	19980203	US 1996-597335	19960206
KR 153500	B1	19981201	KR 1998-10886	19980328
KR 153501	B1	19981201	KR 1998-10887	19980328

PRIORITY APPLN. INFO.:

US 1988-265158	A	19881031
US 1989-421452	B2	19891013
FI 1989-5141	A	19891030
HU 1989-5608	A	19891030
KR 1989-15647	A	19891030
US 1992-900809	B3	19920617

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 114:117859

IT 132219-77-3 132219-78-4 132219-79-5


132219-80-8

RL: BIOL (Biological study)

(bifunctional chelant with ortho ligating functionality)


RN 132219-77-3 CAPLUS

CN Glycine, N,N'-[5-(acetylamino)-2-hydroxy-1,3-phenylene]bis(methylene)bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI)
(CA INDEX NAME)




RN 132219-78-4 CAPLUS

CN Glycine, N,N'-[(5-amino-2-hydroxy-1,3-phenylene)bis(methylene)]bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 132219-79-5 CAPLUS


CN Glycine, N,N'-[(2-hydroxy-5-isothiocyanato-1,3-phenylene)bis(methylene)]bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI)
(CA INDEX NAME)




RN 132219-80-8 CAPLUS
 CN Glycine, N-[5-(acetylamino)-3-[[bis(carboxymethyl)amino]methyl]-2-hydroxyphenyl]methyl-N-[2-bis(carboxymethyl)amino]ethyl- (9CI) (CA INDEX NAME)




IT 132219-77-3P 132219-78-4P 132219-79-5P
 132219-80-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as ortho-ligating chelant)
 RN 132219-77-3 CAPLUS
 CN Glycine, N,N'-[[5-(acetylamino)-2-hydroxy-1,3-phenylene]bis(methylene)]bis[N-[2-bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 132219-78-4 CAPLUS
 CN Glycine, N,N'-[[5-amino-2-hydroxy-1,3-phenylene]bis(methylene)]bis[N-[2-bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 132219-79-5 CAPLUS
 CN Glycine, N,N'-[(2-hydroxy-5-isothiocyanato-1,3-phenylene)bis(methylene)]bis[N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI)
 (CA INDEX NAME)



RN 132219-80-8 CAPLUS
 CN Glycine, N-[[5-(acetilamino)-3-[[bis(carboxymethyl)amino]methyl]-2-hydroxyphenyl]methyl]-N-[2-[bis(carboxymethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2010 ACS on SIN
 ACCESSION NUMBER: 1990:111491 CAPLUS

Correction of: 1988:485711

DOCUMENT NUMBER: 112:111491

Correction of: 109:85711

ORIGINAL REFERENCE NO.: 112:18679a,18682a

TITLE: Development of iron chelators for Cooley's anemia
 AUTHOR(S): Martell, Arthur E.; Motekaitis, Ramunas J.; Murase, Ichiro; Sala, Luis F.; Stoldt, Richard; Ng, Chiu Y.; Rosenkrantz, Harris; Metterville, John J.

